16/06/2021 - General information
On June 15th and 16th, the STOPSTORM consortium coordinated by the UMC Utrecht with the IMIM and Hospital del Mar's participation, met virtually to discuss early project progress. The project, which officially started on May 1st, will begin researching the use of radiotherapy in treating cardiac arrhythmias. Patients who suffer from ventricular tachycardia (fibrillation of the ventricles) are often treated with medication and/or implantation of an ICD, a defibrillator that corrects a rapid heart rate with an electric shock. In cases of persistent arrhythmias that do not respond adequately to regular therapy, patients may undergo invasive catheter ablation. The aim of the consortium, consisting of 31 partners across 8 European countries, is to investigate the option of radiotherapy-ablation for the 30%-50% of patients whose symptoms persist after catheter ablation. The treatment, which is also used in lung oncology, consists of a high dose of radiation administered in a single session.
Més informació "Launch of European research into radiotherapy for cardiac arrhythmias"
15/06/2021 - General information
This year's edition of the charitable initiative, promoted by the Catalan Media Corporation (Corporació Catalana de Mitjans Audiovisuals), raised nearly fourteen million euros to fund research into COVID-19. It was a very special edition that selected two projects led by researchers from Hospital del Mar and the Hospital del Mar Medical Research Institute, as well as a third, joint project, from among the 229 proposals submitted for funding. The Scientific Committee of La Marató de TV3 has decided to fund three research projects on COVID-19 that involve Hospital del Mar and the Hospital del Mar Medical Research Institute. The official announcement was made on 11 June, in a special programme of Al Cotxe presented by Eloi Vila. Two of the studies are led by researchers from the IMIM and Hospital del Mar, while a third is being run jointly with other centres. This latest edition of La Marató raised almost fourteen million euros.
Més informació "Three IMIM and Hospital del Mar projects funded by the 2021 La Marató de TV3"
01/06/2021 - General information
The Jury of the Àngel Prize for Occupational Medicine 2021 has awarded the Prize convened by the Catalan Association of Occupational Health to Dr. Consol Serra Pujadas, in recognition of her dedication to defending health of working people. Consol Serra is the coordinator of the University Pompeu Fabra (UPF) and Hospital del Mar Medical Research Institute (IMIM) Center for research in Occupational Health, Head of the Occupational Health Service of the PSMar and Head of Studies of the "Mateu Orfila-UPF" Occupational Medicine Teaching Unit. The award ceremony will take place on June 15, during the General Assembly of members of the Catalan Association of Occupational Health
Més informació "Consol Serra Angel Award for Occupational Medicine 2021"
19/05/2021 - General information
The consultant in the Pneumology Department at Hospital del Mar and Hospital del Mar Medical Research Institute researcher will be at the helm of this prestigious publication for the next three years. Dr. Esther Barreiro, a consultant in the Pneumology Service at Hospital del Mar and coordinator of the IMIM's Research Group on Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, will be the new editor-in-chief of ERJ Open Research, the official journal of the European Respiratory Society (ERS). Her appointment was announced at the last meeting of the ERS Executive Committee and will take effect in January 2022.
17/05/2021 - General information
The head of the Medical Oncology Service and director of the Cancer Research Programme at the Hospital del Mar Medical Research Institute is one of the most outstanding specialists among Catalan oncologists. The Governance and Economics Coordinates Institute has just published its TOP 100 ranking of the best doctors working in Catalan hospitals, both public and private. Dr. Joan Albanell, head of the Medical Oncology Department at Hospital del Mar, features among the top ten specialists in the oncology section.
12/05/2021 - General information
Montagut has been invited to be part of the group of experts who will draft the European Society of Medical Oncology recommendations on the appropriate use of this technique and its implementation in clinical practice. The head of the Digestive Oncology section in the Medical Oncology Service at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute (IMIM), Dr. Clara Montagut, will be a co-author of the ESMO recommendations for the use of liquid biopsy in cancer patients. The project is led by Professor Nicholas Turner, from the Institute of Cancer Research in London. The initiative is one of the tasks of the organisation's Translational Research and Precision Medicine Working Group.
05/05/2021 - General information
The General Assembly of the ISCIII Clinical Research Support Platform has elected Dr. Ana Aldea, Head of the Clinical Pharmacology Section at Hospital del Mar and coordinator of the IMIM Clinical Research Unit, as a member of the Steering Committee. The ISCIII Clinical Research Support Platform, (SCReN, Spanish Clinical Research Network), is a network structure supporting clinical research and is made up of the 34 units financed in the PT20 call of the Carlos III Health Institute, distributed among hospitals throughout the National Health System (SNS). This network structure, acting in a coordinated manner, will be responsible for executing the actions necessary to achieve the Platform's objectives.
29/04/2021 - General information
The benchmark meeting in the field of immunotherapy cancer treatment was held once again, on April 9, in a hybrid format. This year, the presentations focused on the research and development of this type of treatment for various types of tumours, as well as molecular diagnostics. Understanding which factors make immunotherapy work in some cancer patients and not in others, the structure and genetics of tumours to help select the most appropriate treatment, is the current focus of research in this field. This was evident at the new edition of the Optimizing Immunotherapy, New Approaches, Biomarkers, Sequences and Combinations congress, held on 9 April in a hybrid format and organised by the Hospital del Mar Medical Research Institute (IMIM) and Hospital del Mar. The meeting brought together around twenty of the world's leading experts in research and clinical application of immunotherapy treatments to analyse the latest breakthroughs and the future of immunotherapy. It was backed by the SEOM, SOGUC and CIBERONC.
Més informació "The future of immunotherapy at the Optimizing Immunotherapy Congress"
28/04/2021 - General information
The head of the Epilepsy Unit at Hospital del Mar and coordinator of the Epilepsy Research Group at the Hospital del Mar Medical Research Institute has been appointed Spanish Society of Neurology representative in the field of epilepsy to the top European scientific body in the field of neurology.
23/04/2021 - General information
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven de novo drug design methods in collaboration with Gaylan Bio to rapidly design novel molecules which would bind to the previously 'undruggable' Huntington's Disease target. Huntington's Disease (HD) is a neurodegenerative disorder that affects thousands of patients worldwide. There is currently no cure or disease modifying treatment for HD. This is why US-based company Galyan Bio and Barcelona-based Chemotargets joined efforts to design a first in class drug for HD. The result has been the generation of a first-in-class drug candidate for HD. Galyan Bio plans to start clinical trials in HD in 2022. Galyan Bio's new treatment is intended to slow down the disease in symptomatic patients and delay manifestation of HD in symptom-free gene carriers.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
